UNSPSC 51184002: Carbutamide

This classification denotes an anti-diabetic agent with the molecular formula C11H17N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) E3K8P4869P, chemically known as urea, 1-butyl-3-sulfanilyl- but more generally known as carbutamide, which bears US NIH Compound Identifier 9564. European Medicines Agency schedules Carbutamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06620MIG.

UNSPSC 51184002 Carbutamide is a Commodity code for a specific pharmaceutical product, but state and local procurement activity under this code shows no relevant recent opportunities. The single recent posting tagged to the code—Minnesota Multistate Cooperative Purchasing Alliance's generic multi-source pharmaceuticals RFP issued January 20, 2026—solicits broad-based pharmaceutical sourcing across multiple active ingredients and OTC products rather than carbutamide specifically. The RFP establishes framework agreements for distribution through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson) to participating state and local facilities, with evaluation weighted heavily toward price competitiveness (75 percent) and requiring vendors to meet cGMP and Drug Supply Chain Security Act compliance, maintain relationships with at least two of the three wholesalers with chargeback systems in place, and carry $5 million in general liability and $2 million in network security and professional liability coverage. The mismatch between the code's narrow product scope and the broad pharmaceutical-sourcing activity suggests this Commodity code may not be capturing carbutamide procurement as a line item in current state and local buying patterns, or carbutamide demand through these channels is sufficiently low that it falls into general pharmaceutical frameworks rather than standalone solicitations.

The only recent opportunity of record is MMCAP's RFP, with proposals due March 26, 2026, administered by the Minnesota Department of Administration and spanning Minnesota and Oregon participants. The structure reflects multistate cooperative purchasing leverage, with contract awards effective July 1, 2026 for two-year terms and optional extensions, pricing submitted in multiple formats (flat price, net price, or WAC-minus structures), and a 3 percent administrative fee on all purchases. The absence of additional carbutamide-specific solicitations across states or local jurisdictions suggests limited near-term procurement activity under this code alone; buyers pursuing pharmaceutical opportunities in this space should track broader generic-drug frameworks and cooperative purchasing vehicles rather than expect standalone opportunities for this Commodity code.